Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P20366 (substance P)
 21,176 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Pancreatic duct bicarbonate secretion is mediated primarily by secretin-induced elevation of intracellular cyclic AMP, although little is known of the effects of other physiological regulators on pancreatic duct cyclic AMP metabolism. We investigated the effects of secretin and several other potential agonists on cyclic AMP levels in isolated guinea pig main and interlobular pancreatic duct segments and in cultured duct epithelial monolayers. Secretin (0.1 microM) caused a five- to eightfold elevation of cyclic AMP in both isolated ducts and cultured monolayers (EC50 = 0.15 nM). Main duct segments, while responsive, were less so than segments of interlobular duct. In isolated duct segments, carbachol, bombesin, cholecystokinin, substance P, calcitonin gene-related peptide, glucagon, insulin, isoproterenol, neurotensin, and prostaglandin E2 did not significantly alter resting or secretin-stimulated cyclic AMP levels. In contrast, 0.1 microM vasoactive intestinal peptide significantly increased cyclic AMP to a level comparable to that evoked by an equal concentration of secretin. Somatostatin significantly attenuated the effects of a submaximal (physiological) dose of secretin on duct cyclic AMP levels without altering resting cyclic AMP levels, suggesting that somatostatin's effects on pancreatic duct fluid secretion are mediated by inhibition of adenylyl cyclase activity.
 ...
PMID:Regulation of cyclic AMP levels in guinea pig pancreatic ducts and cultured duct epithelial monolayers. 857 80

Pancreatic duct cells secrete the HCO(3)(-) ions found in pancreatic juice. While the regulatory pathways that stimulate pancreatic ductal HCO(3)(-) secretion are well described, little is known about inhibitory pathways, apart from the fact that they exist. Nevertheless, such inhibitory pathways may be physiologically important in terms of limiting the hydrostatic pressure within the lumen of the duct, and in terms switching off pancreatic secretion after a meal. Methionine encephalin, insulin, somatostatin, peptide YY, substance P, basolaterally applied adenosine triphosphate, arginine vasopressin, 5-hydroxytryptamine and epidermal growth factor have all been shown to inhibit fluid and/or HCO(3)(-) secretion from pancreatic ducts. Importantly, most of these inhibitors have been shown to reduce secretion in isolated pancreatic ducts, so they must act directly on the ductal epithelium. This brief review provides an overview of our current knowledge of the inhibitors, and inhibitory pathways of pancreatic ductal secretion. SIGNALLING NETWORK FACTS: Methionine encephalin, insulin, somatostatin, peptide YY, substance P, basolaterally applied adenosine triphosphate, arginine vasopressin, 5-hydroxytryptamine and epidermal growth factor have all been shown to inhibit fluid and/or HCO(3)(-) secretion from pancreatic ducts. The inhibition of pancreatic secretion can be mediated by indirect (decreased cholinergic or increased adrenergic stimulation, decreased release of stimulatory hormones) and direct (inhibitory hormone or neurotransmitter acting on the duct cells) mechanisms.
 ...
PMID:The inhibitory pathways of pancreatic ductal bicarbonate secretion. 1699 76